Second-Line Treatment and Prognostic Factors ...
Document type :
Compte-rendu et recension critique d'ouvrage
DOI :
Permalink :
Title :
Second-Line Treatment and Prognostic Factors in Neuroendocrine Carcinoma.
Author(s) :
Hadoux, Julien [Auteur]
Département de médecine oncologique [Gustave Roussy]
Walter, Thomas [Auteur]
Université Paris Sciences et Lettres [PSL]
Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe
Centre de Bioinformatique [CBIO]
Kanaan, Christina [Auteur]
Hescot, Segolene [Auteur]
Institut Curie [Paris]
Hautefeuille, Vincent [Auteur]
CHU Amiens-Picardie
Perrier, Marine [Auteur]
Sorbonne Université - Faculté de Médecine [SU FM]
CHU Saint-Antoine [AP-HP]
Tauveron, Igor [Auteur]
Génétique, Reproduction et Développement [GReD]
Laboureau, Sandrine [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Do Cao, Christine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Pétorin, Caroline [Auteur]
Service Chirurgie Digestive et Hépatobiliaire [CHU Clermont-Ferrand]
Blanchet, Odile [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Faron, Matthieu [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Leteurtre, Emmanuelle [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Rousselet, Marie-Christine [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Joubert Zakeyh, Juliette [Auteur]
Marchal, Aude [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Chatelain, Denis [Auteur]
CHU Amiens-Picardie
CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 [CHIMERE]
Beaulaton, Clement [Auteur]
Hervieu, Valerie [Auteur]
Hospices Civils de Lyon [HCL]
Lombard-Bohas, Catherine [Auteur]
Hôpital Edouard Herriot [CHU - HCL]
Ducreux, Michel [Auteur]
Département de médecine oncologique [Gustave Roussy]
Institut Gustave Roussy [IGR]
UNICANCER
Scoazec, Jean Yves [Auteur]
Département de biologie et pathologie médicales [Gustave Roussy]
Baudin, Eric [Auteur]
Département de médecine oncologique [Gustave Roussy]
Département de médecine oncologique [Gustave Roussy]
Walter, Thomas [Auteur]
Université Paris Sciences et Lettres [PSL]
Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe
Centre de Bioinformatique [CBIO]
Kanaan, Christina [Auteur]
Hescot, Segolene [Auteur]
Institut Curie [Paris]
Hautefeuille, Vincent [Auteur]
CHU Amiens-Picardie
Perrier, Marine [Auteur]
Sorbonne Université - Faculté de Médecine [SU FM]
CHU Saint-Antoine [AP-HP]
Tauveron, Igor [Auteur]
Génétique, Reproduction et Développement [GReD]
Laboureau, Sandrine [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Do Cao, Christine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Pétorin, Caroline [Auteur]
Service Chirurgie Digestive et Hépatobiliaire [CHU Clermont-Ferrand]
Blanchet, Odile [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Faron, Matthieu [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Leteurtre, Emmanuelle [Auteur]

Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Rousselet, Marie-Christine [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Joubert Zakeyh, Juliette [Auteur]
Marchal, Aude [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Chatelain, Denis [Auteur]
CHU Amiens-Picardie
CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 [CHIMERE]
Beaulaton, Clement [Auteur]
Hervieu, Valerie [Auteur]
Hospices Civils de Lyon [HCL]
Lombard-Bohas, Catherine [Auteur]
Hôpital Edouard Herriot [CHU - HCL]
Ducreux, Michel [Auteur]
Département de médecine oncologique [Gustave Roussy]
Institut Gustave Roussy [IGR]
UNICANCER
Scoazec, Jean Yves [Auteur]
Département de biologie et pathologie médicales [Gustave Roussy]
Baudin, Eric [Auteur]
Département de médecine oncologique [Gustave Roussy]
Journal title :
Endocrine-related cancer
Pages :
ERC-22-0102
Publisher :
BioScientifica
Publication date :
2022
ISSN :
1351-0088
HAL domain(s) :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie
English abstract : [en]
Neuroendocrine carcinomas (NEC) are aggressive malignant diseases. Etoposide-based rechallenge (EBR) and the prognostic role of Rb status in second-line chemotherapy (2L) have not been studied. The objectives of this study ...
Show more >Neuroendocrine carcinomas (NEC) are aggressive malignant diseases. Etoposide-based rechallenge (EBR) and the prognostic role of Rb status in second-line chemotherapy (2L) have not been studied. The objectives of this study were to report the results of 2L including EBR as well as prognostic factors in a national retrospective multicenter study. NEC patients treated in 2L and further, with tissue samples available were included. Rb status and morphological classification were reviewed centrally. Among the 121 NEC patients (40% female, median age 61) included, there were 73 small cell NEC (60%), 34 large cell NEC (28%) and 14 NEC (not otherwise specified, 12%). Primary sites were lung (39%), gastro-enteropancreatic (36%), other (13%) and unknown (12%). Median Ki-67 index was 80%. Median progression-free survival (PFS) and overall survival (OS) under 2L were 2.1 and 6.2 months, respectively. No difference was observed between patients who received an "Adenocarcinoma-like" or a "Neuroendocrine-like" 2L or according to the Rb status. Thoracic primary was the only adverse prognostic factor for OS. EBR, administered to 31 patients, resulted in a 62% disease control rate with a median PFS and OS of 3.2 and 11.7 months respectively. In the 94 patients with a relapse-free interval ≥q 3 months after first-line platinum-etoposide, median OS was 12 months in patients who received EBR as compared to 5.9 months in patients who did not (p=0.043). EBR could be the best 2L option for patient with initial response to first line platinum-etoposide lasting at least 3 months. Rb status does not provide prognostic information in this setting.Show less >
Show more >Neuroendocrine carcinomas (NEC) are aggressive malignant diseases. Etoposide-based rechallenge (EBR) and the prognostic role of Rb status in second-line chemotherapy (2L) have not been studied. The objectives of this study were to report the results of 2L including EBR as well as prognostic factors in a national retrospective multicenter study. NEC patients treated in 2L and further, with tissue samples available were included. Rb status and morphological classification were reviewed centrally. Among the 121 NEC patients (40% female, median age 61) included, there were 73 small cell NEC (60%), 34 large cell NEC (28%) and 14 NEC (not otherwise specified, 12%). Primary sites were lung (39%), gastro-enteropancreatic (36%), other (13%) and unknown (12%). Median Ki-67 index was 80%. Median progression-free survival (PFS) and overall survival (OS) under 2L were 2.1 and 6.2 months, respectively. No difference was observed between patients who received an "Adenocarcinoma-like" or a "Neuroendocrine-like" 2L or according to the Rb status. Thoracic primary was the only adverse prognostic factor for OS. EBR, administered to 31 patients, resulted in a 62% disease control rate with a median PFS and OS of 3.2 and 11.7 months respectively. In the 94 patients with a relapse-free interval ≥q 3 months after first-line platinum-etoposide, median OS was 12 months in patients who received EBR as compared to 5.9 months in patients who did not (p=0.043). EBR could be the best 2L option for patient with initial response to first line platinum-etoposide lasting at least 3 months. Rb status does not provide prognostic information in this setting.Show less >
Language :
Anglais
Popular science :
Non
Source :
Submission date :
2024-02-17T03:56:02Z